By Karen Roman
OmniScience and INmune Bio, Inc. (Nasdaq: INMB) said they’re using genAI in an Alzheimer’s disease trial.
The AI will support the live clinical trial and is expected to increase efficiency and the probability of success, both companies said in a statement.
“OmniScience and INmune Bio share a vision to transform how clinical trial teams engage with data – transforming data into knowledge in real time and informing decisions that increase the probability of success,” said Angela Holmes, OmniScience’s CEO.
Contact:
